Posted by Michael Wonder on 20 Feb 2025
BioRestorative receives FDA fast track designation for BRTX-100 chronic lumbar disc disease program
20 February 2025 - Reflects positive preliminary Phase 2 safety and efficacy data reported to date.
BioRestorative Therapies today announced that the US FDA has granted fast track designation to the BRTX-100 program for the treatment chronic lumbar disc disease.
